Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by equities researchers at Robert W. Baird in a report issued on Friday. They currently have a $102.00 price objective on the stock. Robert W. Baird’s price objective would indicate a potential upside of 162.48% from the stock’s current price.
SRPT has been the topic of several other research reports. Leerink Swann raised Sarepta Therapeutics from an “underperform” rating to a “market perform” rating and set a $50.00 target price on the stock in a research note on Monday, September 19th. Piper Jaffray Cos. upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a report on Monday, September 19th. Janney Montgomery Scott set a $30.00 target price on Sarepta Therapeutics and gave the stock a “hold” rating in a report on Wednesday, August 3rd. William Blair upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Monday, September 19th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $66.81.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 3.5440% on Friday, hitting $37.4828. 456,173 shares of the company traded hands. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The company’s market capitalization is $1.80 billion. The stock’s 50-day moving average price is $51.21 and its 200-day moving average price is $28.99.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Thursday, October 27th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.37. During the same period last year, the company posted ($1.25) EPS. On average, equities analysts predict that Sarepta Therapeutics will post ($4.25) earnings per share for the current year.
In other news, insider Sandesh Mahatme sold 30,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $50.08, for a total transaction of $1,502,400.00. Following the completion of the transaction, the insider now directly owns 61,532 shares in the company, valued at approximately $3,081,522.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $154,000. Winslow Evans & Crocker Inc. acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $209,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $211,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 65.05% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.